C4 Therapeutics Q2 net loss narrows to $17.7M; cash $295.7M; CFT1946 ESMO data Sept 14

C4 Therapeutics, Inc.

2023-Q1 EPS reported -$0.67 revenue$15,045,000

Revenue $12.0M vs $2.7M YoY, driven by $8M Biogen milestone.
Net loss $17.7M ($0.26 per share) vs $35.9M ($0.73) in Q2 2023.
Cash $295.7M; expects runway into 2027.
CFT1946 Phase 1 monotherapy data to be presented at ESMO Congress 2024 on Sept 14.
Cemsidomide Phase 1 data in MM and NHL on track for Q4 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.